Clinical trial
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of…
NCT02973789 · NovoCure GmbH, Industry · Completed
Key facts
| NCT number | NCT02973789 |
|---|---|
| Title | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) |
| Official title | LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure |
| Lead sponsor | NovoCure GmbH, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Nonsmall Cell Lung Cancer, NSCLC |
| Intervention type | Device, Drug |
| Interventions | NovoTTF-200T, Immune checkpoint inhibitors or docetaxel |
| Enrollment | 276 |
| Start date | Dec 1, 2016 |
| Primary completion | Sep 24, 2024 |
| Completion | Oct 9, 2024 |
| First posted | Nov 25, 2016 |
| Last update posted | Oct 21, 2024 |
| Countries | Austria, Belgium, Bulgaria, Canada, China, Croatia, Czechia, France, Germany, Hong Kong, Hungary, Italy and 6 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: